Andrew G Polson

List of Publications by Year
in descending order

32 papers	1,915 citations	361045 20 h-index	454577 30 g-index
32 all docs	32 docs citations	32 times ranked	2502 citing authors

#	Article	IF	Citations
1	Antibody-Drug Conjugates for the Treatment of Nonâ€“Hodgkin's Lymphoma: Target and Linker-Drug Selection. Cancer Research, 2009, 69, 2358-2364.	0.4	229
2	Therapeutic potential of an anti-CD79b antibodyâ€“drug conjugate, antiâ€“CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma. Blood, 2009, 114, 2721-2729.	0.6	205
3	An anti-CD3/antiâ€“CLL-1 bispecific antibody for the treatment of acute myeloid leukemia. Blood, 2017, 129, 609-618.	0.6	136
4	Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma. Blood, 2007, 110, 616-623.	0.6	135
5	Antitumor Efficacy of a Bispecific Antibody That Targets HER2 and Activates T Cells. Cancer Research, 2014, 74, 5561-5571.	0.4	135
6	Targeting LGR5 ⁺ cells with an antibody-drug conjugate for the treatment of colon cancer. Science Translational Medicine, 2015, 7, 314ra186.	5.8	131
7	A Novel Anti-CD22 Anthracycline-Based Antibodyâ€“Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs. Clinical Cancer Research, 2015, 21, 3298-3306.	3.2	124
8	Expression pattern of the human FcRH/IRTA receptors in normal tissue and in B-chronic lymphocytic leukemia. International Immunology, 2006, 18, 1363-1373.	1.8	100
9	Cathepsin B Is Dispensable for Cellular Processing of Cathepsin B-Cleavable Antibodyâ€“Drug Conjugates. Cancer Research, 2017, 77, 7027-7037.	0.4	99
10	DCDT2980S, an Anti-CD22-Monomethyl Auristatin E Antibodyâ€“Drug Conjugate, Is a Potential Treatment for Non-Hodgkin Lymphoma. Molecular Cancer Therapeutics, 2013, 12, 1255-1265.	1.9	72
11	Investigational antibody-drug conjugates for hematological malignancies. Expert Opinion on Investigational Drugs, 2011, 20, 75-85.	1.9	64
12	FcRL5 as a Target of Antibodyâ€“Drug Conjugates for the Treatment of Multiple Myeloma. Molecular Cancer Therapeutics, 2012, 11, 2222-2232.	1.9	63
13	An Antiâ€“CLL-1 Antibodyâ€“Drug Conjugate for the Treatment of Acute Myeloid Leukemia. Clinical Cancer Research, 2019, 25, 1358-1368.	3.2	53
14	In vivoeffects of targeting CD79b with antibodies and antibody-drug conjugates. Molecular Cancer Therapeutics, 2009, 8, 2937-2946.	1.9	45
15	The successes and limitations of preclinical studies in predicting the pharmacodynamics and safety of cellâ€surfaceâ€targeted biological agents in patients. British Journal of Pharmacology, 2012, 166, 1600-1602.	2.7	37
16	Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma. Blood Cancer Journal, 2019, 9, 17.	2.8	35
17	Intratumoral Payload Concentration Correlates with the Activity of Antibodyâ€“Drug Conjugates. Molecular Cancer Therapeutics, 2018, 17, 677-685.	1.9	30
18	Antibodyâ€“drug conjugates for the treatment of B-cell non-Hodgkinâ€™s lymphoma and leukemia. Future Oncology, 2013, 9, 355-368.	1.1	27

#	Article	IF	Citations
19	Antibody Drug Conjugates Differentiate Uptake and DNA Alkylation of Pyrrolobenzodiazepines in Tumors from Organs of Xenograft Mice. Drug Metabolism and Disposition, 2016, 44, 1958-1962.	1.7	23
20	A homogeneous high-DAR antibodyâ€“drug conjugate platform combining THIOMAB antibodies and XTEN polypeptides. Chemical Science, 2022, 13, 3147-3160.	3.7	23
21	Antiâ€CD22 and antiâ€CD79b antibodyâ€drug conjugates preferentially target proliferating B cells. British Journal of Pharmacology, 2017, 174, 628-640.	2.7	22
22	Exposure-Efficacy Analysis of Antibody-Drug Conjugates Delivering an Excessive Level of Payload to Tissues. Drug Metabolism and Disposition, 2019, 47, 1146-1155.	1.7	20
23	Stabilizing a Tubulysin Antibodyâ€“Drug Conjugate To Enable Activity Against Multidrug-Resistant Tumors. ACS Medicinal Chemistry Letters, 2017, 8, 1037-1041.	1.3	19
24	Evaluation and use of an antiâ€cynomolgus monkey CD79b surrogate antibodyâ€“drug conjugate to enable clinical development of polatuzumab vedotin. British Journal of Pharmacology, 2019, 176, 3805-3818.	2.7	18
25	A BCMA/CD16A bispecific innate cell engager for the treatment of multiple myeloma. Leukemia, 2022, 36, 1006-1014.	3.3	17
26	Antibodyâ€“Drug Conjugates Derived from Cytotoxic seco-CBI-Dimer Payloads Are Highly Efficacious in Xenograft Models and Form Protein Adducts In Vivo. Bioconjugate Chemistry, 2019, 30, 1356-1370.	1.8	15
27	Preclinical pharmacokinetics and pharmacodynamics of DCLL9718A: An antibody-drug conjugate for the treatment of acute myeloid leukemia. MAbs, 2018, 10, 1312-1321.	2.6	13
28	Toward an Effective Targeted Chemotherapy for Multiple Myeloma. Clinical Cancer Research, 2009, 15, 3906-3907.	3.2	11
29	An Antiâ€“CD22-seco-CBI-Dimer Antibodyâ€“Drug Conjugate (ADC) for the Treatment of Non-Hodgkin Lymphoma That Provides a Longer Duration of Response than Auristatin-Based ADCs in Preclinical Models. Molecular Cancer Therapeutics, 2021, 20, 340-346.	1.9	9
30	Novel Anti-LY6G6D/CD3 T-Cellâ€“Dependent Bispecific Antibody for the Treatment of Colorectal Cancer. Molecular Cancer Therapeutics, 2022, 21, 974-985.	1.9	5
31	Antibodyâ€“Drug Conjugates for the Treatment of B-Cell Malignancies. , 2013, , 139-147.		0
32	Antibody-Drug Conjugates Targeted to CD79 for the Treatment of Non-Hodgkinâ€™s Lymphoma.. Blood, 2006, 108, 2524-2524.	0.6	0